Two phase III trials find that the daily oral GLP-1 receptor agonist orforglipron (Foundayo) improves sleep-disordered breathing in adults with moderate-to-severe obstructive sleep apnea and overweight or obesity. In Medical Xpress’s report, the medication is associated with significantly fewer breathing interruption episodes over one year compared with placebo.
MedPage Today similarly describes benefits for sleep apnea outcomes in the same patient group, framing the results around improved breathing during sleep in both phase III studies. Medical Xpress emphasizes that the findings are “late-breaking” science presented at the American Heart Association’s Scientific Sessions 2026 and highlights the one-year comparison with placebo. MedPage Today focuses more generally on trial evidence of improvement in sleep-disordered breathing, without adding presentation details.